Markets
Oracle Wall Street Revisions
(CSA Archive/Getty Images)

Analysts revise up anything and everything they thought about Oracle

After the company’s bombshell earnings this week, Wall Street thinks Oracle’s trajectory has changed.

As the week’s trading comes to a close, Oracle’s earnings bombshell continues to be digested by Wall Street, with analysts writing up a range of estimates for the company over the coming years.

Over the last day alone, JPMorgan equity analysts upped their price target for the stock, lifting it to $270 from a relatively low $210. (That’s still a pretty big undershoot of the current consensus of nearly $330, which implies a nearly 13% gain for the stock over the next 12 to 18 months.)

Analysts at Bernstein Research, on the other hand, lifted their price target on the stock to $363 from $308, citing an “exceptional growth trajectory” for the company’s cloud business. And Barclays analysts upgraded their target to $347 from $281.

“We still sense that many investors are not fully aligned with the notion that Oracle will be a main AI beneficiary and hence, expect ongoing upside momentum for the name,” Barclays analysts wrote.

But from the looks of rising estimates across a number of metrics, Oracle has made considerable progress this week in changing its image among the investing public from an incredibly profitable — but dull as dishwater — cloud computing and business software behemoth to a major player in the AI revolution.

Following on the massive build in the company’s key RPO metric — essentially booked orders that haven’t yet turned into actual sales dollars — disclosed during the company’s results, analysts have ratcheted up their estimates of sales growth over the coming years.

They now see annual sales returning to the remarkable level of more than 40% by fiscal 2028. (It has been almost 30 years since Oracle sales growth cracked 40%, which it did in fiscal 1996.)

Earnings per share are also expected to notch records over the next three fiscal years as well, with year-over-year growth climbing to 13%, 18%, and 36% by fiscal 2028.

To be sure, it should be stressed that these are, after all, estimates — statistical expressions of the conventional wisdom on Wall Street.

That conventional wisdom could be on the money. Or untidy elements of reality could intervene and make this story a lot messier.

For instance, in order to collect its many billions in backlogged RPO sales the company announced this week, Oracle will have to invest billions and billions of dollars to build out the data infrastructure it needs to provide services to customers like OpenAI.

And in the near term, that’s going to eat up a flood of sales dollars coming through the door, something that Wall Street estimates also captured this week.

In Oracle’s post-earnings conference call with analysts, company CEO Safra Catz explained elegantly how interrelated the company’s capital expenditure plans are with its RPO order backlog:

“Given our RPO growth, I now expect fiscal year 2026 CapEx will be around $35 billion. As a reminder, the vast majority of our CapEx investments are for revenue-generating equipment that is going into the data centers and not from land or buildings. As we bring more capacity online, we will convert the large RPO backlog into accelerating revenue and profit growth.”

Sounds like a good plan. And judging by the share price move this week and the follow-on upgrades to Wall Street price targets and earnings and sales estimates, people think it’s likely to work.

But the history of massive investment booms — from the emergence of railroads, to Japanese real estate, to the dot-com boom and the US housing bust — suggests there is plenty of scope for these things not to go exactly as everybody expects. But for now, the party continues.

More Markets

See all Markets
markets

Rocket lab soars to new record close amid rally for retail faves

Rocket Lab ripped by roughly 10% Friday to close at a new all-time high, riding an upturn of retail enthusiasm for a coterie of tech-themed favorites, even as the broader market was more or less flat on the day.

Goldman Sachs’ basket of “retail favorites” — its heaviest weights are Reddit, AppLovin, and Tempus AI — was the second-biggest gainer among the company’s flagship US equity baskets on Friday, rising about 1.6%. The S&P was almost dead flat.

It’s not Rocket Lab’s first retail rodeo, as the money-losing company has more than doubled this year and is up nearly 700% over the last 12 months.

markets

Six Flags pops after reiterating its guidance as theme park attendance rebounds

Six Flags shares rose more than 7% today after the company reported a rebound in attendance and early season pass sales heading into the fall. The nine-week period ended August 31 saw 17.8 million guests, up about 2% from the same stretch last year, with stronger momentum in the final four weeks. 

More importantly, Six Flags reaffirmed its full-year adjusted EBITDA guidance of $860 million to $910 million, showing confidence that its cost and operations strategy can stay strong for the duration of the year. Riding that wave, Six Flags also said early 2026 season pass unit sales are pacing ahead of last year, and average season pass prices are up about 3%.

The good vibes come despite a drop in in-park per-capita spending, especially from admissions, where promotions and changes to attendance mix (which parks or days guests visit) have weighed. Earlier this week, the amusement giant signed a new agreement that extended its position as the exclusive amusement park partner for Peanuts™ in North America through 2030.

Despite the rally, Six Flags shares are down about 52% year to date.

markets

Rivian turns red on the year, squeezed by a recall and the looming end of the EV tax credit

Shares of EV maker Rivian are down more than 5% on Friday following the company’s recall of 24,214 vehicles due to a software issue. The stock move erases Rivian’s year-to-date gain and turns the company negative on the year.

Rivian’s 2025 model year R1S and R1T are affected by the defect, which was identified after a vehicle’s hands-free highway assist software failed to identify another vehicle on the road, causing a low-speed collision. Rivian said it’s released an over-the-air update to fix the issue.

The recall marks Rivian’s fifth this year, affecting nearly 70,000 of its vehicles.

Rivian’s shares are down more than 20% from their 2025 high, which came prior to the passage of President Trump’sbig, beautiful bill.” Through the legislation, the $7,500 EV tax credit is set to expire at the end of the month.

markets

Moderna, Pfizer dip after WaPo reports Trump officials’ plan to link Covid vaccines to child deaths

Vaccine makers are falling after The Washington Post reported that the Trump administration plans to link the coronavirus vaccine to 25 child deaths.

Moderna and Pfizer, the two companies who sell the vaccine in the US, fell by more than 5% and 2%, respectively. The coronavirus vaccine is virtually the only revenue driver for Moderna, while Pfizer has a larger and more diverse portfolio.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.